Browse Lab Results > 2014-0037
Trial Summary
About CDAS Project, PI, Publications: Expanded evaluation of markers of human papillomavirus (HPV) infection and cancer at multiple anatomic sites - using PLCO data to bolster the cohort consortium effort
Datasets
Site: Multiple
Inclusion Criteria:
- All I-Arm
- Has Biochemical Consent
- No Rare Cancers in Non-Cases
- Has Followup Time (At least 1 day)
- Not in 2011-0281 or 2014-0037
- Has Any Serum
- Has Pre-DX Material
- Matched at a 2-1 Ratio
Matching Factors:
- Gender
- Age at randomization (5 year groups)
- Race (W/B/O)
- Year of birth (5 year groups)
- Year of blood draw
Match Ratio: 2 to 1
Match Technique: Frequency matching only non-cases as controls.
Additional Matching Comments: 2-1 match accounting for the selection of serial samples
Analytes:
- HPV 11E6
- HPV 11E7
- HPV 11L1
- HPV 16E1 FL
- HPV 16E2
- HPV 16E4
- HPV 16E6
- HPV 16E7
- HPV 16L1
- HPV 18E1 FL
- HPV 18E2
- HPV 18E4
- HPV 18E6
- HPV 18E7
- HPV 18L1
- HPV 31E6
- HPV 31E7
- HPV 31L1
- HPV 33E6
- HPV 33E7
- HPV 33L1
- HPV 35E6
- HPV 35E7
- HPV 35L1
- HPV 45E6
- HPV 45E7
- HPV 45L1
- HPV 52E6
- HPV 52E7
- HPV 52L1
- HPV 58E6
- HPV 58E7
- HPV 58L1
- HPV 6BE6
- HPV 6BE7
- HPV 6L1
- Herpes Simplex Virus 2 2mgG unique
- Human Polyomavirus BK VP1
- Human Polyomavirus HPyV6 VP1
- Human Polyomavirus JC VP1
- Tumor Protein P53
Number of Cases: 139
Number of Controls: 278
Site: Anogenital
Inclusion Criteria:
- All I-Arm
- Has Biochemical Consent
- No Prior History of Cancer
- No Rare Cancers in Controls
- Has Follow-up Time (at least 1 day)
- Has Serum
- Has Pre-DX Serum (Eligible)
- Matched 4-1 (Selected)
Matching Factors:
- Gender
- Race (White/Black/Other)
- Year of Birth
- Study Year of Exit
- Study Year of Material
- Draw Date in 6 Month Blocks
Match Ratio: 4 to 1
Match Technique: Frequency matching only non-cases as controls.
Analytes:
- Cell Protein P16
- Epstein-Barr Virus EA-D
- Epstein-Barr Virus EBNA truncated
- Epstein-Barr Virus VCA p18
- Epstein-Barr Virus Zebra
- HPV 11E6
- HPV 11E7
- HPV 11L1
- HPV 16E1 FL
- HPV 16E2
- HPV 16E6
- HPV 16E7
- HPV 16L1
- HPV 18E6
- HPV 18E7
- HPV 18L1
- HPV 1L1
- HPV 31E6
- HPV 31E7
- HPV 31L1
- HPV 33E6
- HPV 33E7
- HPV 33L1
- HPV 45E6
- HPV 45E7
- HPV 45L1
- HPV 52E6
- HPV 52E7
- HPV 52L1
- HPV 58E6
- HPV 58E7
- HPV 58L1
- HPV 6BE2
- HPV 6BE6
- HPV 6BE7
- HPV 6L1
- HPV 8L1
- Herpes Simplex Virus 2 2mgG unique
- Human Polyomavirus BK VP1
- Human Polyomavirus JC VP1
- Tumor Protein P53
Number of Cases: 73
Number of Controls: 292
Site: Head and Neck
Inclusion Criteria:
- All I-Arm
- BQ Returned
- Has Biochemical Consent
- Has Any Serum
- Has Pre-DX Material
- In Desired Population
- Has Pre-DX Serum in Unmeasured Year
Matching Factors:
- N
- o
- n
- e
Match Ratio: Not Applicable
Match Technique: Not Applicable
Analytes:
- Cell Protein P16
- Epstein-Barr Virus EA-D
- Epstein-Barr Virus EBNA truncated
- Epstein-Barr Virus Zebra
- HPV 11E6
- HPV 11E7
- HPV 11L1
- HPV 16E1 FL
- HPV 16E2
- HPV 16E4
- HPV 16E6
- HPV 16E7
- HPV 16L1
- HPV 18E1 FL
- HPV 18E2
- HPV 18E4
- HPV 18E6
- HPV 18E7
- HPV 18L1
- HPV 31E6
- HPV 31E7
- HPV 31L1
- HPV 33E6
- HPV 33E7
- HPV 33L1
- HPV 45E6
- HPV 45E7
- HPV 45L1
- HPV 58E6
- HPV 58E7
- HPV 58L1
- HPV 6BE2
- HPV 6BE6
- HPV 6BE7
- HPV 6L1
- Hepatitis C Virus 1aCore (1.4)
- Hepatitis C Virus 1aNS3 (2.5)
- Herpes Simplex Virus 2 2mgG unique
- Human Polyomavirus BK VP1
- Human Polyomavirus JC VP1
- Tumor Protein P53
Number of Cases: 73
Number of Controls: 8